




Study			
Study Sponsor	Anokion	Provention Bio	9 Meters Biopharma
Phase	Phase 1	Phase 2b	Phase 3
Approximate Length of Participation	<i>Participants choose Group A or B</i> Group A: 7 weeks Group B: 8 weeks	36 weeks	30 weeks
Approximate Number of Study Site Visits	Group A: 5 visits Group B: 6 visits	17 visits	8 visits
Gluten Challenge	Optional	No	No
Endoscopy with Biopsy	No	Yes	Optional
Medication Name	KAN-101	PRV-015	Larazotide
Medication Type	IV infusion	Injection	Oral capsule
Medication Description	Designed to create immune tolerance to gluten antigens by targeting the liver	Designed to block IL-15, a protein which triggers intestinal inflammation and damage in celiac patients	Designed to restore "leaky" junctions in the intestine to reduce inflammation caused by gluten
Chance of Receiving Placebo	Group A: No placebo Group B: 1 in 4	1 in 4	1 in 3
Must be following a gluten-free diet to participate?	Yes, 12+ months	Yes, 12+ months	Yes, 6+ months
Must be actively experiencing celiac disease symptoms to participate?	No	Yes	Yes
Compensation available?	Yes	Yes	Yes
Travel Reimbursement Available?	Yes	Yes	Yes
Age Requirement	18-70	18-70	18+
Study Site Locations	US	US & Canada	US & Canada
Learn More	Anokion.com/ACeD	proactiveceliac.com	celiac-study.com/cdf
See If You Qualify	iqualify.celiac.org	survey.proactiveceliac.com/r/refcdf	iqualify.celiac.org